Anti-inflammatory activities of a new VEGF blocker, Conbercept.
Conbercept
angiogenesis
collagen-induced arthritis
vascular endothelial growth factor
xylene-inducible ear edema
Journal
Immunopharmacology and immunotoxicology
ISSN: 1532-2513
Titre abrégé: Immunopharmacol Immunotoxicol
Pays: England
ID NLM: 8800150
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
pubmed:
18
8
2021
medline:
27
1
2022
entrez:
17
8
2021
Statut:
ppublish
Résumé
Angiogenesis and inflammation exhibit a mutually reinforcing relationship in many human diseases. Vascular endothelial growth factor (VEGF) is one of the most important proangiogenic mediators. Conbercept is a novel VEGF inhibitor. Type II collagen-induced rat rheumatoid arthritis (CIA) model was established to evaluate the anti-chronic inflammation activities of Conbercept. ELISA was used to measure the concentrations of immune factors in the blood of arthritis rats. The xylene-induced ear edema was conducted to evaluate the effect of Conbercept on acute inflammation. Our results showed that Conbercept significantly reduced the paw edema volume and the arthritis index in CIA rats. Furthermore, we found that Conbercept decreased the serum levels of vascular endothelial growth factor (VEGF), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in CIA rats. Xylene-induced ear edema is a widely used method to study acute inflammation. Conbercept significantly inhibited xylene-induced ear edema. All results indicate that Conbercept exhibits significant inhibition of acute and chronic inflammation.
Sections du résumé
BACKGROUND
BACKGROUND
Angiogenesis and inflammation exhibit a mutually reinforcing relationship in many human diseases. Vascular endothelial growth factor (VEGF) is one of the most important proangiogenic mediators. Conbercept is a novel VEGF inhibitor.
METHOD
METHODS
Type II collagen-induced rat rheumatoid arthritis (CIA) model was established to evaluate the anti-chronic inflammation activities of Conbercept. ELISA was used to measure the concentrations of immune factors in the blood of arthritis rats. The xylene-induced ear edema was conducted to evaluate the effect of Conbercept on acute inflammation.
RESULT AND DISCUSSION
CONCLUSIONS
Our results showed that Conbercept significantly reduced the paw edema volume and the arthritis index in CIA rats. Furthermore, we found that Conbercept decreased the serum levels of vascular endothelial growth factor (VEGF), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in CIA rats. Xylene-induced ear edema is a widely used method to study acute inflammation. Conbercept significantly inhibited xylene-induced ear edema.
CONCLUSION
CONCLUSIONS
All results indicate that Conbercept exhibits significant inhibition of acute and chronic inflammation.
Identifiants
pubmed: 34402367
doi: 10.1080/08923973.2021.1959608
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Recombinant Fusion Proteins
0
Vascular Endothelial Growth Factor A
0
vascular endothelial growth factor A, rat
0
KH902 fusion protein
1P05PW62F3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM